Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 7675 results

  1. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  2. Nutrition: improving maternal and child nutrition (QS98)

    This quality standard covers improving nutrition for pregnant women, and babies and children under 5 and their mothers and carers. It focuses on low-income and disadvantaged families. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    1 July 2015
    View quality statements

    Sections for QS98

  3. Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]

    In development [GID-TA11392] Expected publication date: 27 November 2024

    Technology appraisal guidance
    In development

  4. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA867

  5. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA869

  6. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

    NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

    Technology appraisal guidance
    Published
    23 January 2013

    Sections for TA273

  7. Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

    NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

    Technology appraisal guidance
    Published
    28 October 2015

    Sections for TA362

  8. Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

    NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

    Technology appraisal guidance
    Published
    27 November 2013

    Sections for TA302

  9. Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)

    NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..

    Technology appraisal guidance
    Published
    25 February 2015

    Sections for TA334

  10. Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

    NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with

    Technology appraisal guidance
    Published
    22 May 2013

    Sections for TA286

  11. Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)

    NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...

    Technology appraisal guidance
    Published
    12 December 2012

    Sections for TA270

  12. Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)

    NICE is unable to make a recommendation about the use in the NHS of bendamustine for treating indolent (low grade) non-Hodgkin's lymphoma that is refractory

    Technology appraisal guidance
    Published
    27 October 2010

    Sections for TA206

  13. Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

    NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence

    Technology appraisal guidance
    Published
    27 October 2010

    Sections for TA207

  14. Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)

    NICE is unable to recommend the use in the NHS of agomelatine for the treatment of major depressive episodes because no evidence submission was received from the manufacturer or sponsor of the technology.

    Technology appraisal guidance
    Published
    27 July 2011

    Sections for TA231

  15. Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

    NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

    Technology appraisal guidance
    Published
    27 January 2016

    Sections for TA382